Skip to content
Triangle logo TriangleGet started
← Study library

NCT02158052 · REGISTRY CONDITION SEARCH

Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
NA
Status at capture
COMPLETED
Registry last update
2022-12-13

This pilot trial offers the unique opportunity for both the treatment of multiple myeloma or systemic AL amyloidosis for which hematopoietic stem cell transplantation would be ordinarily indicated and the reversal of end-stage renal failure, while avoiding the risks associated with long-term standard anti-rejection therapy used in renal transplantation. The primary objectives of this study are to assess renal allograft tolerance (that is, the acceptance of the kidney without the need for anti-rejection therapy), assess anti-tumor response rates in multiple myeloma and AL amyloidosis, and assess complication rates for genetically (HLA) matched related donor combined bone marrow and kidney transplantation using a low dose total body irradiation based preparative regimen.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant

→

outcome · POSTED

Anti-Tumor Response Rate

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Participant Inclusion Criteria * Participants with end-stage renal failure due to or in association with multiple myeloma or systemic AL amyloidosis which hematopoietic cell transplantation is appropriate and a ≥ 50% five-year survival probability with transplantation is expected. This includes, but is not limited to: * Multiple myeloma (MM), ISS stage II or III in complete or very good partial remission * AL amyloidosis without significant cardiac disease * Males or females 18 - 65 years of age. * Participants must have an HLA-matched or one of six HLA A, B, or DR antigen-mismatched related donor, with high resolution molecular class I and II allele typing. * Men and women of reproductive potential must agree to use a reliable method of birth control during the treatment, and women should do so for a period of 2 years following the transplant. * Participants should be on dialysis or have a CrCl \<20 ml/min. * Patients should not have evidence of renal recovery of their renal failure over a 90 day period of therapy for their underlying malignancy or other blood disorder. * . * Patients with a history of other malignancies excluding basal cell carcinoma of the skin and carcinoma in situ of the cervix with a disease-free survival interval of \>2 years. Patients with the following malignancies must demonstrate a 5 year disease-free survival: * Breast cancer with positive nodes * Malignant melanoma (other than in situ) * Colorectal cancer (other than Dukes Stage A or B1) * Patients with multiple myeloma must have received previous treatment with a bortezomib-based regimen. Patients with AL amyloidosis must have received previous treatment with a bortezomib-based regimen and/or autologous stem cell transplantation * Patients with a history of malignant melanoma must be reviewed by an independent oncologist prior to enrollment. * Recipient ability to understand and provide informed consent. Participant Exclusion Criteria * Evidence of active infection as defined by: a) clinical syndrome consistent with viral or bacterial infection (e.g., influenza, URI, UTI) or b) fever with a clinical site of infection identified, or c) microbiologically documented infection, including, but not limited to, bacteremia or septicemia. * Participation in other investigational drug use at the time of enrollment. * Contraindication to therapy with any one of the proposed agents (e.g., history of allergy to horse serum in ATG). * Serologic positivity to HIV or HCV. * Women of childbearing age in whom adequate contraception cannot be maintained. * AST/ALT \> 3 x normal or bilirubin \> 1.5 x normal (unless due to Gilbert's syndrome). * Pregnancy or uncontrolled serious medical illness not related to underlying myeloma. * Cardiac ejection fraction \< 40% by echocardiogram. * FEV1 \< 50% predicted or corrected DLCO \< 50% predicted. * ABO blood group incompatibility in the host-vs-graft direction. * Diagnosis of myelodysplastic syndrome Donor Inclusion Criteria * HLA-matched or one of six HLA A, B, or DR antigen-mismatched related male or female donor 18-65 years of age. * ECOG performance status 0 or 1. * Excellent health per conventional pre-donor history (medical and psychosocial evaluation). * Acceptable laboratory parameters (hematology in normal or near-normal range; liver function \< 2 times the upper limit of normal and normal creatinine). * Compatible ABO blood group. * Negative donor lymphocyte crossmatch. * No positive testing for viral infection (HbsAg, HIV, HCV, HTLV-1). * Cardiac/Pulmonary evaluation within normal limits (CXR, EKG). * Donor ability to understand and provide informed consent.
healthy Volunteers
false
maximum Age
65 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    combined bone marrow and kidney transplantation
    intervention Names
    1. Drug: Tacrolimus
    2. Drug: Equine Anti-thymocyte globulin
    3. Procedure: Kidney transplant from a related donor
    4. Drug: Bone marrow transplant from a related donor
    5. Radiation: Total body irradiation 400 centigray (200 cGy X 2)
    label
    Bone Marrow and Kidney RECIPIENTS
    type
    EXPERIMENTAL
  2. description
    Donors who donate bone marrow and kidney
    intervention Names
    1. Procedure: Kidney transplant from a related donor
    label
    Bone Marrow and Kidney DONORS
    type
    OTHER
interventions
  1. arm Group Labels
    1. Bone Marrow and Kidney RECIPIENTS
    description
    Tacrolimus starting on Day -1
    name
    Tacrolimus
    type
    DRUG
  2. arm Group Labels
    1. Bone Marrow and Kidney RECIPIENTS
    description
    20 mg/kg IV on Days -3, -1, +1, +3
    name
    Equine Anti-thymocyte globulin
    type
    DRUG
  3. arm Group Labels
    1. Bone Marrow and Kidney DONORS
    2. Bone Marrow and Kidney RECIPIENTS
    description
    On Day 0 the renal transplant is performed according to standard surgical techniques.
    name
    Kidney transplant from a related donor
    type
    PROCEDURE
  4. arm Group Labels
    1. Bone Marrow and Kidney RECIPIENTS
    description
    Donor bone marrow (\> 2 x 10e8 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed.
    name
    Bone marrow transplant from a related donor
    type
    DRUG
  5. arm Group Labels
    1. Bone Marrow and Kidney RECIPIENTS
    description
    On transplant day -1
    name
    Total body irradiation 400 centigray (200 cGy X 2)
    type
    RADIATION
Study design
allocation
NON_RANDOMIZED
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
2
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    The Primary Outcome is: the incidence of renal allograft rejection at 6 months post-transplant
    measure
    Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant
    time Frame
    6 Months
secondary Outcomes
  1. description
    This is measurement is summarized via bone marrow biopsy results and blood assays through 3 years. Anti-tumor response is assessed according to Center for International Blood and Marrow Transplant Research (CIBMTR.org) criteria. For multiple myeloma, based on assessment of serum and urine immunofixation, the presence or absence of soft tissue plasmacytomas and analyses of bone marrow aspirate and biopsy samples, response categories include stringent complete remission (sCR), complete remission (CR), near CR (nCR) very good partial response (VGPR), partial response (PR), stable disease (SD), and progressive disease (PD). For AL amyloidosis, based on assessment of serum and urine immunofixation and serum free light chain ratio, hematologic response categories include complete response, very good partial response, partial response, no response/stable disease and progressive disease. Organ responses are also assessed according to organ specific criteria.
    measure
    Anti-Tumor Response Rate
    time Frame
    3 years
Full study description
brief Summary
This pilot trial offers the unique opportunity for both the treatment of multiple myeloma or systemic AL amyloidosis for which hematopoietic stem cell transplantation would be ordinarily indicated and the reversal of end-stage renal failure, while avoiding the risks associated with long-term standard anti-rejection therapy used in renal transplantation. The primary objectives of this study are to assess renal allograft tolerance (that is, the acceptance of the kidney without the need for anti-rejection therapy), assess anti-tumor response rates in multiple myeloma and AL amyloidosis, and assess complication rates for genetically (HLA) matched related donor combined bone marrow and kidney transplantation using a low dose total body irradiation based preparative regimen.
detailed Description
The induction of transplantation tolerance involves the specific elimination of the immune response to the transplant but not to other antigens. In the realm of kidney transplantation, tolerance means that the recipient is unable to detect the donor transplant kidney as foreign, and therefore the recipient is unable to reject the kidney. Donor bone marrow engraftment leads to kidney graft tolerance in animal models. Renal failure is a major complication of multiple myeloma and AL amyloidosis for which the only known cure is allogeneic bone marrow transplantation. Standard bone marrow transplantation is associated with prohibitive toxicities in patients with end stage renal disease, and is generally not considered an option for those patients. Patients with multiple myeloma and AL amyloidosis are excluded from conventional renal transplantation protocols because of their underlying malignancy. A less toxic bone marrow transplantation protocol, utilizing low dose total body irradiation and anti-thymocyte globulin, combined with renal transplantation, could provide an opportunity for cure of the myeloma or amyloidosis and correction of end stage renal disease. In addition, successful marrow engraftment may be expected to lead to a state of tolerance. Successful implementation of tolerance would be a major benefit to transplant recipients. The significance of developing tolerance is that the patient could be spared the disabling complications of indefinite immunosuppression, which include infections, cataracts, osteoporosis, diabetes, atherosclerosis, hypertension, and malignancy.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-657ffc5691351c9706cd
      requested nct id
      NCT02158052
      primary nct id
      NCT02158052
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      b044aded380b5ab352fa7a91996994c1cbf49714cc987da4fc92794fccb9075c
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-657ffc5691351c9706cd
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02158052
      occurrences
      1. context exact
        NCT02158052
        end
        11
        exact text
        NCT02158052
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/393/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      0a21c3cdfd9fd435cc0278804fd20b83177c52f1e9a44921e99f1ad80415bd43

    Preserved source evidence · Not medical advice